Inclisiran in the treatment of dyslipidemia:a rapid health technology assessment
10.12173/j.issn.1005-0698.202501050
- VernacularTitle:英克司兰治疗血脂异常的快速卫生技术评估
- Author:
Lingbin CHEN
1
;
Weiping PAN
;
Zhou CHEN
;
Wentan XU
Author Information
1. 福建医科大学药学院(福州 350122)
- Publication Type:Journal Article
- Keywords:
Inclisiran;
Dyslipidemia;
Efficacy;
Safety;
Cost-effectiveness;
Rapid health technology assessment
- From:
Chinese Journal of Pharmacoepidemiology
2025;34(10):1198-1205
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy,safety and economy of inclisiran in the treatment of dyslipidemia by rapid health technology assessment,and to provide evidence-based basis for clinical treatment.Methods PubMed,Web of Science,Embase,Cochrane Library,CNKI,WanFang Data,VIP,SinoMed databases,and official websites of health technology assessment(HTA)institutions were systematically searched to collect HTA reports,systematic reviews/Meta-analysis and pharmacoeconomic studies on inclisiran for the treatment of dyslipidemia from inception to December 31,2024.Two researchers independently screened the literature,extracted information and performed quality assessment of the included literature,and then qualitative synthesis and analysis of the findings were conducted.Results A total of 8 studies were included,comprising 7 systematic reviews/Meta-analysis and 1 pharmacoeconomic study.In terms of efficacy,inclisiran significantly reduced low-density lipoprotein cholesterol,apolipoprotein B,total cholesterol,triglycerides and non-high-density lipoprotein cholesterol levels in patients with dyslipidemia compared to placebo.In terms of safety,the incidence of adverse drug reactions associated with inclisiran did not differ significantly from that of placebo,with the most common adverse drug reactions being mild injection site reactions.In terms of cost-effectiveness,the current price of inclisiran made its combination therapy with statins economically unfavorable compared to statin monotherapy.Conclusion The efficacy and safety of inclisiran in the treatment of dyslipidemia are good.However,due to its current pricing,the combination therapy of inclisiran with statins is not yet cost-advantageous compared to statin monotherapy in clinical practice.
